Instem Life Science Systems plc : Change of Name

Change of Name

18 January 2012

Instem Life Science Systems plc
("Instem" or the "Company")

Change of Name

Instem Life Science Systems plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, announces that with effect from 13 January 2012, the Company has changed its name to Instem plc to simplify its corporate branding. The Company's ticker/ TIDM remains the same: INS.L. At the same time, BioWisdom Limited (acquired in March 2011) has been renamed Instem Scientific Limited.

For further information, please contact:

Instem plc	[phone]
Phil Reason, CEO
Nigel Goldsmith, CFO
Brewin Dolphin - Nominated Adviser, Financial Adviser & Broker	[phone]
Aubrey Powell
Luke Boyce
Newgate Threadneedle	[phone]
Caroline Evans-Jones
Fiona Conroy

About Instem plc

Instem (AIM:INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

In March 2011 Instem acquired BioWisdom Limited, a leading provider of software solutions for extracting intelligence from R&D related healthcare data. The acquisition broadened and strengthened Instem's Centrus™ product suite, accelerating the product development roadmap.

Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Company employs over 110 people in six offices in the U.S, UK, and China; with additional resource locations in India and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.